ArticleJournal of the American Heart Association2025
Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeted therapies in non-small cell lung cancer and their cardiovascular impact: mechanisms, clinical profiles, and strategies of management.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe discovery of driver mutations has transformed advanced non-small cell lung cancer treatment, with ALK (anaplastic lymphoma kinase)-rearranged patients achieving longest overall survival. However, the risk of cancer therapy-related cardiovascular diseases (CTRCVDs) is underrecognized, particularly comparing second-generation ALK-tyrosine kinase inhibitors alectinib and brigatinib to the third-generation tyrosine kinase inhibitor lorlatinib, which offers the longest progression-free survival. We aimed to compare CTRCVDs risks among patients with lung cancer receiving ALK-tyrosine kinase inhibitor, assess incidence trends, and identify clinical risk factors associated with ALK-tyrosine kinase inhibitor-related CTRCVDs.
methodsThis retrospective cohort study of 946 848 adults with lung cancer (2010-2024) using TriNetX compared CTRCVDs risk in ALK-mutated patients treated with lorlatinib versus brigatinib/alectinib. After excluding ROS1-mutated cases and 1:1 propensity score matching, 744 patients per group were analyzed. CTRCVDs, defined as myocardial infarction, stroke, arterial embolism, or heart failure, were evaluated with Kaplan-Meier analysis and Cox proportional hazards models over 2 years.
resultsLorlatinib treatment was associated with a significantly increased risk of CTRCVDs (hazard ratio [HR], 3.00 [95% CI, 1.65-5.45];
conclusionThese findings underscore the importance of routine cardiovascular monitoring, particularly in older patients and those with atrial arrhythmias.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.